Argenx Se ARGX
NASDAQ ARGX
$1,038.85 -14.61 (-1.39%)
As of: Sep 4, 2026 · 10:51 AM EDT

Argenx Se (ARGX) Research & Development (2016 - 2026)

Argenx Se's (ARGX) quarterly Research & Development came in at $1.4 billion in Q2 2026, up 518.68% YoY from $221.8 million in Q2 2025, and up 409.71% on a QoQ basis from -$443.0 million in Q1 2026.

Analysis

Argenx Se (ARGX) Research & Development (2016 - 2026) Analysis & Trends

Argenx Se (ARGX) has 11 years of Research & Development data on file, last reported at $1.4 billion in Q2 2026.

  • Quarterly Research & Development rose 518.68% year-over-year to $1.4 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $201.6 million (up 117.21% YoY) and the FY2025 annual result came in at $1.4 billion, up 38.71% from the prior year.
  • Research & Development grew to $1.4 billion in Q2 2026, from -$443.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $1.4 billion in Q2 2026 to a low of -$443.0 million in Q1 2026.
  • A 5-year average of -$163.5 million and a median of -$230.6 million in 2024 frame the typical range for Research & Development.
  • Annual changes were most pronounced in 2023 — Research & Development sank 107.29% — and 2026, when it surged 518.68%.
  • Tracing ARGX's Research & Development over 5 years: stood at -$147.8 million in 2022, then slumped by 107.29% to -$306.4 million in 2023, then advanced by 2.98% to -$297.2 million in 2024, then decreased by 25.06% to -$371.7 million in 2025, then surged by 469.1% to $1.4 billion in 2026.
  • The last three Research & Development figures came in at $1.4 billion (Q2 2026), -$443.0 million (Q1 2026), and -$371.7 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Vertex Pharmaceuticals 139.68 Bn 131.82 Bn 2.84 Bn 993.80 Mn
2 Regeneron Pharmaceuticals 85.68 Bn 77.68 Bn 3.93 Bn 1.63 Bn
3 Argenx Se 63.67 Bn 58.48 Bn 1.37 Bn -486.00 Mn
4 Moderna 57.02 Bn 51.88 Bn 52.00 Mn 651.00 Mn
5 Revolution Medicines 43.83 Bn 43.83 Bn - 394.92 Mn
6 BeOne Medicines 39.97 Bn 34.87 Bn 1.53 Bn 612.28 Mn
7 Alnylam Pharmaceuticals 35.23 Bn 31.93 Bn 992.69 Mn 413.13 Mn
8 Royalty Pharma 28.56 Bn 27.72 Bn - 97.90 Mn
9 Insmed 27.54 Bn 26.38 Bn 358.27 Mn 210.03 Mn
10 Incyte 25.49 Bn 20.95 Bn 1.57 Bn 516.95 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -486.00 Mn
Mar 31, 2026 -443.00 Mn
Dec 31, 2025 -371.71 Mn
Sep 30, 2025 -355.65 Mn
Jun 30, 2025 -327.70 Mn
Mar 31, 2025 -311.00 Mn
Dec 31, 2024 -297.23 Mn
Sep 30, 2024 -235.94 Mn
Jun 30, 2024 -225.29 Mn
Mar 31, 2024 -224.97 Mn
Dec 31, 2023 -306.37 Mn
Sep 30, 2023 -191.76 Mn
Jun 30, 2023 -195.51 Mn
Mar 31, 2023 -165.86 Mn
Dec 31, 2022 -147.80 Mn
Sep 30, 2022 -236.68 Mn
Jun 30, 2022 -126.92 Mn
Mar 31, 2022 -151.97 Mn
Dec 31, 2021 -167.17 Mn
Sep 30, 2021 -139.44 Mn